Adrenomedullin plasma levels predict left ventricular reverse remodeling after cardiac resynchronization therapy

Area of Science:

• Cardiology
• Biomarkers in Heart Failure

Background:

• Elevated adrenomedullin (ADM) in heart failure (HF) is linked to fluid retention and sympathetic nervous system activation.
• Cardiac resynchronization therapy (CRT) is a treatment for HF, but predicting patient response remains a challenge.

Purpose of the Study:

• To investigate the association between pre-treatment plasma ADM levels and treatment response in HF patients undergoing CRT.
• To identify if ADM can serve as a predictive biomarker for reverse remodeling after CRT.

Main Methods:

• Fifty patients with NYHA Class III-IV HF and LVEF < 35% received CRT.
• Plasma ADM and BNP levels, along with echocardiographic parameters, were measured before CRT implantation.
• Patients were categorized into two groups based on reduction in end-systolic dimensions (ESD) post-CRT.

Main Results:

• Patients with a significant reduction in ESD (Group I) showed significantly higher baseline ADM levels compared to those with minimal ESD change (Group II) (27.2 ± 1.8 pmol/l vs 17.9 ± 1.4 pmol/l, P = 0.0003).
• Higher baseline ADM levels were associated with successful reverse remodeling, indicated by a ≥1 NYHA class improvement in 38 patients.
• No significant differences were observed between groups regarding age, sex, LVEF, BNP, or QRS duration.

Conclusions:

• Elevated baseline plasma ADM levels identify a subgroup of heart failure patients likely to experience reverse remodeling after CRT.
• Lower baseline ADM levels may indicate advanced cardiac dysfunction, suggesting a poorer prognosis and limited benefit from CRT.